Key regions: Australia, Germany, United Kingdom, United States, France
The Immunosuppressants market in EAEU has been growing steadily in recent years.
Customer preferences: Immunosuppressants are used to prevent rejection of transplanted organs and to treat autoimmune diseases, such as rheumatoid arthritis and psoriasis. The demand for these drugs is driven by the increasing prevalence of these conditions in the EAEU region. Patients are also becoming more aware of the benefits of these drugs and are seeking them out as a means of managing their conditions.
Trends in the market: One trend in the Immunosuppressants market in EAEU is the increasing use of biologics. These drugs are made from living cells and are highly effective in treating autoimmune diseases. They are also more expensive than traditional immunosuppressants. As a result, the market is shifting towards higher-priced biologics, which are expected to continue to drive growth in the market.Another trend in the market is the increasing use of generic drugs. As patents expire on branded drugs, generic versions become available at lower prices. This has led to increased competition in the market, which is expected to further drive down prices.
Local special circumstances: One of the special circumstances in the EAEU region is the high incidence of hepatitis C. This has led to an increased demand for immunosuppressants, as these drugs are often used to treat the condition. The EAEU region also has a large population of elderly people, who are more likely to suffer from autoimmune diseases and require immunosuppressant treatment.
Underlying macroeconomic factors: The EAEU region has experienced steady economic growth in recent years, which has led to increased healthcare spending. This has helped to drive growth in the Immunosuppressants market, as more people are able to afford these drugs. However, the region still faces challenges in terms of access to healthcare, particularly in rural areas. This has limited the growth of the market to some extent.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
